StockNews.AI
HOWL
StockNews.AI
1 min

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

1. Werewolf Therapeutics presents three posters at SITC 2025 meeting. 2. Novel therapies targeting immune activation for cancer treatment are highlighted. 3. WTX-124 and WTX-330 show promise against solid tumors without systemic toxicity. 4. Research focuses on conditional T cell engagers to mitigate side effects. 5. Company aims to leverage proprietary platform for new therapeutic candidates.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming SITC presentation could generate positive investor interest, similar to past oncology presentations that boosted stocks like Amgen.

How important is it?

The reported advancements and clinical focus suggest future potential for drug approvals and partnerships, which can positively influence stock prices.

Why Long Term?

The results from these presentations could lead to increased market confidence, impacting stock performance over months as developments unfold.

Related Companies

AMGNMRNABMY
October 03, 2025 09:00 ET  | Source: Werewolf Therapeutics, Inc. WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicityAbstract Number: 861Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit Halls A and B1) Title: Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicityAbstract Number: 964Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit Halls A and B1) Title: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulationAbstract Number: 862Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10- 6:35 p.m.Location: Poster Hall (Exhibit Halls A and B1) About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit www.werewolftx.com. WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved. Investor Contact:Dan FerryLifeSci Advisors617.430.7576daniel@lifesciadvisors.com Media Contact:Amanda SellersDeerfield Group301.332.5574amanda.sellers@deerfieldgroup.com Company Contact:Timothy TrostChief Financial OfficerWerewolf Therapeuticsttrost@werewolftx.com

Related News